01535nam a2200265   4500001000800000005001700008007000300025008004100028040000800069041000800077100003600085245005500121300002500176520071000201650001900911650004900930650003100979650002401010650002301034650003001057700002401087773011001111942003101221999001701252ESSALUD20260903093950.0ta      t        pe ||||| |||| 00| 0 spa d  aBMG  aeng  aDer, Channing J. eAutor954512  aAdvances in RAS therapeutics for pancreatic cancer  apáginas: 1857-1861  aSomatic mutations in the Kirsten rat sarcoma viral oncogene homologue (KRAS) occur in more than 90% of pancreatic ductal adenocarcinomas. In this issue of the Journal, Wolpin et al. evaluated the side-effect profile of and response to a first-in-class small-molecule drug called daraxonrasib, which targets the active state of RAS (see Key Concepts) in patients with metastatic pancreatic ductal adenocarcinoma who have received at least one previous line of chemotherapy. In the context of second-line treatment, they reported an objective response according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, in up to 35% of patients and a median response duration of 8.2 months.  aCÁNCER91231  aCÁNCER DEL TRACTO GASTROINTESTINAL 953776  aGASTROENTEROLOGÍA912562  aHEMATOLOGÍA97422  aONCOLOGÍA912240  aGENÉTICA GENERAL954107  aYeh, Jen Jen9545130 022717922676dMassachusetts NEJM GroupoNEJM015tThe New England Journal of Medicine wESSALUDx0028-4793  cARTICULOSe2026-08-31zsqb  c22915d22915